<?xml version="1.0" encoding="UTF-8"?>
<p>In addition to chemical medicines, another vital form of therapy for COVID-19 may be the use of biologics. Currently, interferon-
 <italic>α</italic>2b nebulization of 100,000 to 400,000 IU/kg twice a day for 5 to 7 days is one of the main treatments for COVID-19 in children, and it has demonstrated efficacy in reducing the viral load during early stages of infection [
 <xref rid="B208" ref-type="bibr">208</xref>, 
 <xref rid="B209" ref-type="bibr">209</xref>]. Another promising biologic drug is convalescent plasma, the plasma of patients who have recovered from COVID-19 [
 <xref rid="B210" ref-type="bibr">210</xref>, 
 <xref rid="B211" ref-type="bibr">211</xref>]. Antibodies in the donated plasma could confer temporary, passive immunity against COVID-19, allowing patients time to develop active immunity. Clinical trials are currently ongoing [
 <xref rid="B212" ref-type="bibr">212</xref>, 
 <xref rid="B213" ref-type="bibr">213</xref>], and preliminary results announced from the Chinese hospitals have been promising.
</p>
